Cargando…

Sample Preparation Strategies for Antibody-Free Quantitative Analysis of High Mobility Group Box 1 Protein

Sickness behavior and fatigue are induced by cerebral mechanisms involving inflammatory cytokines. High mobility group box 1 (HMGB1) is an alarmin, and a potential key player in this process. Reliable quantification methods for total HMGB1 and its redox variants must be established in order to clear...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kvivik, Ingeborg, Jonsson, Grete, Omdal, Roald, Brede, Cato
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8230321/ https://www.ncbi.nlm.nih.gov/pubmed/34205112 http://dx.doi.org/10.3390/ph14060537

Ejemplares similares

High mobility group box 1 and a network of other biomolecules influence fatigue in patients with Crohn’s disease
por: Kvivik, Ingeborg, et al.
Publicado: (2023)

Anti-HMGB1 auto-Abs influence fatigue in patients with Crohn’s disease
por: Kvivik, Ingeborg, et al.
Publicado: (2021)

Interleukin-1-related activity and hypocretin-1 in cerebrospinal fluid contribute to fatigue in primary Sjögren’s syndrome
por: Bårdsen, Kjetil, et al.
Publicado: (2019)

Heat-shock protein 90α in plasma reflects severity of fatigue in patients with Crohn’s disease
por: Grimstad, Tore, et al.
Publicado: (2019)

Heat shock proteins and chronic fatigue in primary Sjögren’s syndrome
por: Bårdsen, Kjetil, et al.
Publicado: (2016)

Fatigue in primary Sjögren’s syndrome: A proteomic pilot study of cerebrospinal fluid
por: Larssen, Eivind, et al.
Publicado: (2019)

Neurofilament light is a biomarker of brain involvement in lupus and primary Sjögren’s syndrome
por: Tjensvoll, Anne B., et al.
Publicado: (2020)

Free Light Chains, High Mobility Group Box 1, and Mortality in Hemodialysis Patients
por: Lacquaniti, Antonio, et al.
Publicado: (2022)

Major bioactive chemical compounds in Astragali Radix samples from different vendors vary greatly
por: Kafle, Bijay, et al.
Publicado: (2021)

Naturally acquired anti-high mobility group box 1 antibodies during septic shock
por: Sauneuf, B, et al.
Publicado: (2009)

High-mobility group box 1: role in ARDS
por: Ishizaka, A, et al.
Publicado: (2005)

High‐Mobility Group Box‐1 and Liver Disease
por: Gaskell, Harriet, et al.
Publicado: (2018)

High mobility group box 1 in diabetic nephropathy
por: Shi, Haitao, et al.
Publicado: (2017)

High Mobility Group Box 1 in Human Cancer
por: Rapoport, Bernardo L., et al.
Publicado: (2020)

Induction of arthritis by high mobility group box chromosomal protein 1 is independent of tumour necrosis factor signalling
por: Pullerits, Rille, et al.
Publicado: (2008)

High-mobility group box (TOX) antibody a useful tool for the identification of B and T cell subpopulations
por: Maestre, Lorena, et al.
Publicado: (2020)

Fatigue in celiac disease: A review of the literature
por: Skjellerudsveen, Berit M, et al.
Publicado: (2019)

Fatigue is common and severe in patients with mastocytosis
por: Omdal, Roald, et al.
Publicado: (2018)

High mobility group box 1: as a 'testament' mediator
por: Maruyama, I, et al.
Publicado: (2005)

The Role of High Mobility Group Box 1 in Innate Immunity
por: Lee, Shin-Ae, et al.
Publicado: (2014)

High Mobility Group Box Protein-1 in Wound Repair
por: Ranzato, Elia, et al.
Publicado: (2012)

High-Mobility Group Box 1 in Dry Eye Inflammation
por: Lema, Carolina, et al.
Publicado: (2018)

The Role of High Mobility Group Box 1 in Ischemic Stroke
por: Ye, Yingze, et al.
Publicado: (2019)

Role of High-Mobility Group Box-1 in Liver Pathogenesis
por: Khambu, Bilon, et al.
Publicado: (2019)

High Mobility Group Box 1 Protein in Cerebral Thromboemboli
por: Essig, Fabian, et al.
Publicado: (2021)

Urinary and serum levels of high mobility group box 1
por: Nakamura, Toshihiko, et al.
Publicado: (2023)

High-mobility group box 1 potentiates antineutrophil cytoplasmic antibody-inducing neutrophil extracellular traps formation
por: Ma, Yun-Hua, et al.
Publicado: (2016)

Anti-high Mobility Group Box 1 Antibody Ameliorates Albuminuria in MRL/lpr Lupus-Prone Mice
por: Watanabe, Haruki, et al.
Publicado: (2017)

Anti-High Mobility Group Box 1 Neutralizing-Antibody Ameliorates Dextran Sodium Sulfate Colitis in Mice
por: Chen, Liping, et al.
Publicado: (2020)

Cell-Free DNA, High-Mobility Group Box-1, and Procalcitonin Concentrations in Dogs With Gastric Dilatation–Volvulus Syndrome
por: Troia, Roberta, et al.
Publicado: (2018)

Less, but not gone—gluten-free diet effects on fatigue in celiac disease: a prospective controlled study
por: Skjellerudsveen, Berit Mære, et al.
Publicado: (2023)

Anti-high mobility group box protein 1 monoclonal antibody downregulating P-glycoprotein as novel epilepsy therapeutics
por: de Liyis, Bryan Gervais, et al.
Publicado: (2022)

Identification and Characterization of the Lamprey High-Mobility Group Box 1 Gene
por: Pang, Yue, et al.
Publicado: (2012)

Expression and Effects of High-Mobility Group Box 1 in Cervical Cancer
por: Pang, Xiaoao, et al.
Publicado: (2014)

High Mobility Group Box 1 Expression in Oral Inflammation and Regeneration
por: Yamashiro, Keisuke, et al.
Publicado: (2020)

High Mobility Group Box-1 and Blood–Brain Barrier Disruption
por: Nishibori, Masahiro, et al.
Publicado: (2020)

The Roles of High Mobility Group Box 1 in Cerebral Ischemic Injury
por: Gou, Xiaoyun, et al.
Publicado: (2020)

Role of Glycated High Mobility Group Box-1 in Gastric Cancer
por: Kishi, Shingo, et al.
Publicado: (2021)

High Mobility Group Box 1 Protein Induction by Mycobacterium Bovis BCG
por: Hofner, Péter, et al.
Publicado: (2007)

Bench-to-bedside review: High-mobility group box 1 and critical illness
por: Fink, Mitchell P
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_4hedsna46s48g9prl121cvc59r